Unprofitable Diabetes Drug Developer Files for Hong Kong IPO
Clinical-stage diabetes drug developer Hua Medicine has filed for an initial public offering (IPO) in Hong Kong, the second pharmaceutical firm to do so since the bourse lowered the listing threshold for money-losing biotech firms.
The Shanghai-based company lost 322 million yuan ($50.4 million) in the first quarter of 2018 and lost 280 million yuan in all of 2017, according to its application on Wednesday.
It has chosen Goldman Sachs (Asia) LLC and CLSA Capital Markets Ltd. as joint sponsors of the IPO.
Hua, founded by Li Chen, a former senior executive of Swiss drugmaker Roche AG, has exclusive worldwide rights to Dorzagliatin, used to treat diabetes, under a 2011 deal with Roche.
The company is conducting third-phase clinical trials of Dorzagliatin in China, after which Hua Medicine can apply to put it on the market. It said in the application to the Hong Kong Stock Exchange that it expects to announce the results of the trial in the second half of 2019 and plans to move to the next step by 2020. It also wishes to eventually make the drug available in other markets.
The drug is used to treat Type 2 diabetes, a chronic condition that affects the way the body processes blood sugar. In 2017, there were 453 million diabetes cases globally, and 95% were Type 2, of which China had the largest group, or 120 million patients, according to consultancy Frost & Sullivan.
The diabetes-medicine market in China will grow from 51.2 billion yuan last year to 174 billion yuan in 2028, up by 11.8% annually, F&S said.
Hua Medicine is the second drugmaker to file for a Hong Kong IPO since the local bourse in April paved the listing path for qualified money-losing biotech companies. Ascletis Pharma Inc., a developer of anti-viral, cancer and fatty liver disease drugs, applied in May for an IPO in Hong Kong.
Hua Medicine’s pipeline also includes a drug for a Parkinson’s-related disease, which is expected to start phase-one clinical trials in the first half of next year.
Contact reporter Coco Feng (email@example.com)
Apr 02 18:19
Apr 02 15:27
Apr 02 14:02
Apr 02 13:46
Apr 02 09:22
Apr 01 16:00
Apr 01 15:51
Apr 01 13:31
Apr 01 10:40
Apr 01 03:10
Apr 01 03:06
Mar 31 18:19
Mar 31 17:11
Mar 31 13:09
- 1In Virus-Ravaged Wuhan, Hours-Long Queues to Collect the Ashes of the Dead
- 2Gallery: Bereaved Families of Wuhan Finally Allowed to Collect Their Loved Ones’ Remains
- 3China for First Time Reveals Its Number of Asymptomatic Coronavirus Cases
- 4Zhejiang Covid-19 Infection Highlights Threat from Asymptomatic Carriers
- 5In Depth: How a Rugged Covid-19 Recovery Risks More Than 100 Million Jobs
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas